Experimental mRNA injection takes on tough cancers
NCT ID NCT07040943
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new mRNA-based drug called IL-22BP in 6 adults with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and can shrink cancer. The study focuses on safety and tumor response, not a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL-22BP mRNA injection
What this could lead to
If it works, this could point toward a new treatment option for patients with hard-to-treat solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 6 participants, so it is too small to prove effectiveness. The main goal is safety, and there is no guarantee the treatment will shrink tumors or work for others.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiation Oncology
RECRUITINGChengdu, Sichuan, 610000, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact